6533b852fe1ef96bd12aa361

RESEARCH PRODUCT

Mitotane Concentrations Influence Outcome in Patients With Advanced Adrenocortical Carcinoma

Carla ScaroniSilvia Della CasaSoraya PuglisiMassimo TorlontanoMarco RussoPaola BerchiallaAlessandra QuirinoPaola PerottiBarbara AltieriAnna CalabreseAntonio StiglianoMaria Cristina De MartinoFrancesco FerraùFilippo CeccatoGiuseppe BadalamentiRosario PivonelloGiorgio ArnaldiPaola LoliLetizia CanuVittoria BasileLaura SabaMassimo Terzolo

subject

OncologymitotaneCancer Researchmedicine.medical_specialtyMultivariate analysisrecurrenceCombination therapyPrognosimedicine.medical_treatment030209 endocrinology & metabolismDiseaselcsh:RC254-282behavioral disciplines and activitiessurvivalArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenocortical carcinomaMitotaneIn patientadrenal cancerObjective responseadrenal cancer; mitotane; prognosis; recurrence; survivalChemotherapybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisprognosisbusinessAdrenal cancer Mitotane Prognosis Recurrence Survivalmedicine.drug

description

Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding the impact of plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients with advanced ACC treated with mitotane for &ge

10.3390/cancers12030740http://hdl.handle.net/11573/1393259